These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

If there is any truth to the nursery rhyme “April showers bring May flowers,” you can get ready for allergy season and eczema flareups when the weather gets warmer. Depending on where you live, ...

Nektar Therapeutics' REZPEG shows progress in treating atopic dermatitis & alopecia areata. Click here to find out why I rate ...

The latest update atopic dermatitis guidelines include the new approval of lebrikizumab and the expanded use of baricitinib ...

Galderma has shared positive two-year data for its monoclonal antibody Nemluvio (nemolizumab) in moderate-to-severe atopic ...

Arcutis Biotherapeutics has enrolled the first child in an open-label Phase II trial of Zoryve (roflumilast) for atopic ...

The estimated drug-treated population may grow to over 25,100,000 people. The atopic dermatitis (AD) market across seven ...

The VIASKIN peanut patch (VP250) is safe and effective for children aged 1 to 3 years who have peanut allergy, with and without atopic comorbidities.

ABBV eyes $24.7 billion from Skyrizi and Rinvoq in 2025 as ex-Humira growth offsets sharp sales drop post-U.S. patent loss.

Phase 2 study to evaluate investigational, once-daily ZORYVE .05% in infants as young as 3 months to less than 2 years with atopic dermatitisAtopic dermatitis impacts 9.6 million children in the ...

SHEPPARTON, VICTORIA, AUSTRALIA, June 10, 2025 /EINPresswire.com/ -- Akaal Pharma Pty Ltd Announces Positive Phase-2 Results for S1P1 Agonist in the Treatment of Atopic Dermatitis and Associated ...